V5P.F VYTRUS BIOTECH EO -01
- Market cap
- EUR 98.2M
- P/E
- 23.7x
- P/B
- 7.35x
- ROE
- 28.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is V5P.F undervalued?
Graham numberV5P.F trades 178.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VYTRUS BIOTECH EO -01 fundamental analysis
No fundamental analysis for VYTRUS BIOTECH EO -01 yet.
VYTRUS BIOTECH EO -01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum …
Full company profileVYTRUS BIOTECH EO -01 financial statements
VYTRUS BIOTECH EO -01 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.80M | 3.68M | 3.74M | 5.04M | 8.37M |
| Gross Profit | 3.25M | 4.13M | 4.35M | 5.50M | 8.83M |
| Operating Income | 430K | 645K | 454K | 1.00M | 3.18M |
| EBITDA | - | 1.34M | 1.18M | 1.83M | 4.16M |
| Net Income | 450K | 605K | 545K | 1.02M | 2.90M |
| EPS | 0.07 | 0.09 | 0.08 | 0.14 | 0.39 |
| Balance Sheet | |||||
| Total Assets | 7.18M | 8.00M | 9.31M | 11.1M | 14.7M |
| Total Liabilities | 2.93M | 3.25M | 4.02M | 3.84M | 4.35M |
| Shareholders' Equity | 4.25M | 4.75M | 5.29M | 7.29M | 10.3M |
| Cash & Short-term Investments | 1.28M | 725K | 1.10M | 2.53M | 3.38M |
| Cash Flow | |||||
| Operating Cash Flow | 448K | 1.03M | 904K | 1.84M | 3.90M |
| Capital Expenditure | 272K | 1.29M | 1.17M | 1.20M | 2.68M |
| Free Cash Flow | 176K | -269K | -262K | 640K | 1.22M |
| Ratios | |||||
| ROE | 10.6% | 12.7% | 10.3% | 14.0% | 28.1% |
| ROA | 6.3% | 7.6% | 5.9% | 9.2% | 19.8% |
| Net Profit Margin | 16.0% | 16.4% | 14.6% | 20.2% | 34.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VYTRUS BIOTECH EO -01 dividends
VYTRUS BIOTECH EO -01 has not paid dividends in the last 5 fiscal years.
Who owns VYTRUS BIOTECH EO -01
- Insiders 64.47%
- Institutions 1.28%
- Public & others 34.25%
- Shares outstanding 7.52M
- Free float 3.77M
VYTRUS BIOTECH EO -01 company profile
- Company name
- VYTRUS BIOTECH EO -01
- Ticker
- V5P.F
- ISIN
- ES0105618005
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 47
- Fiscal year end
- December
- Address
- 121 Sant Gaietà, Barcelona, Spain, 08221
- Phone
- 34 93 127 81 06
- Website
- vytrus.com
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects against oxidative stress. The company also provides Baolift that improves muscle tone and facial complexion; Elaya Renova that boosts hair tensegrity; Kannabia Sense, a prebiotic treatment that stimulates the skin microbiota to produce an in-situ postbiotic cocktail; Quora Noni to avoid the attack of skin harmful bacteria; Centella Reversa for facial complexion improvement; and Arabian Cotton to protect and repair cell structures against sun damage. In addition, it offers Photobiome, a prebiotic active that fights the skin photoageing process; Nectaria Lithops, an active ingredient that biophysically optimizes the skin microenvironment and vitamin D levels; Olea Vitae, a cellular oil against ageing; Turmeria Zen for skin hydration and wrinkles on stressed profiles; and Sensia Carota, a plant-based active that protects and prevents from the damage on sensitive and sensitized skins. Further, the company provides technology solutions, such as plasma rich in cell factors; phyto-peptidic, phyto-lipidic, and phyto-glucidic fractions; and phyto-cell fusions, as well as Vytrus TV to create an audiovisual space with added value for cosmetic formulation. It exports its products. Vytrus Biotech, S.A. was incorporated in 2009 and is headquartered in Barcelona, Spain.
VYTRUS BIOTECH EO -01 management
10- Mr. Albert Jane FontCo-Founder, Co-CEO, President, Member of Management Board & Director
- Mr. Oscar Exposito TarresCo-Founder, Co-CEO, C.S.O, Member of Management Board & Director
- Mr. Jordi Rovira MartinezCFO, Member of Management Board, Secretary of the Board & Director
- Mr. Daniel RobustilloSales Director & Member of Management Board
- Mr. Manel LopezCOO & Member of Management Board
- Ms. Sara LaplanaExecutive CSO & Member of Management Board
- Gloria RuizAccounting Director
- Alejandro GuiradoCommunication & Marketing Manager
- Conxita RusinesESG & People Wellbeing Manager
- Marta RomeroFinance Controller